Study guide

5.2: Mechanisms of Action: Respiratory, CNS, & Endocrine Agents

Overseas Pharmacist Readiness Assessment OPRA

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1: About the OPRA Exam 1.2: Study and Preparation Strategy for OPRA

2 Chapter 2: Biomedical Sciences

2.1: Human Physiology & Homeostasis 2.2: Pathophysiology of Major Organ Systems 2.3: Medical Microbiology & Infectious Pathogens 2.4: Immunology & Immunotherapy 2.5: Body Fluids, Electrolytes, & Acid-Base Balance 2.6: Physiological Values & Clinical Lab Interpretations

3 Chapter 3: Medicinal Chemistry & Biopharmaceutics

3.1: Physicochemical Properties of Drugs 3.2: Biopharmaceutics & Formulation Science 3.3: Chemical Stability & Storage of Pharmaceuticals 3.4: Sterile Compounding & Pharmaceutical Microbiology

4 Chapter 4: Pharmacokinetics & Pharmacodynamics

4.1: Principles of Pharmacokinetics (Absorption & Distribution) 4.2: Drug Metabolism & Elimination Pathways 4.3: Quantitative Pharmacokinetics (Vd, Clearance, Half-life, Steady-state) 4.4: Clinical Pharmacokinetics (Dosing Adjustments & Non-linear Kinetics) 4.5: Pharmacodynamics & Receptor Theory

5 Chapter 5: Pharmacology & Toxicology

5.1: Mechanisms of Action: Cardiovascular & Renal Agents 5.2: Mechanisms of Action: Respiratory, CNS, & Endocrine Agents 5.3: Adverse Drug Reactions & Drug-Drug Interactions 5.4: Clinical Toxicology & Poisoning Management 5.5: Pharmacogenomics & Genetic Polymorphism

6 Chapter 6: Therapeutics & Patient Care

6.1: Pharmaceutical Calculations: Doses & Unit Conversions 6.2: Pharmaceutical Calculations: Infusions, Percentages, & Tonicity 6.3: Cardiovascular Therapeutics (Hypertension, Heart Failure, Dyslipidemia) 6.4: Anticoagulation & Antiplatelet Therapy 6.5: Endocrine & Metabolic Therapeutics (Diabetes & Thyroid) 6.6: Respiratory Therapeutics (Asthma & COPD) 6.7: Infectious Disease Therapeutics & Antimicrobial Stewardship 6.8: Central Nervous System & Mental Health Therapeutics 6.9: Gastrointestinal & Renal Therapeutics 6.10: Therapeutics in Special Populations: Pregnancy & Lactation 6.11: Therapeutics in Special Populations: Paediatrics & Geriatrics 6.12: Primary Health Care, Self-Care, & Harm Minimisation 6.13: Professional Practice, Ethics, & Communication

5.2: Mechanisms of Action: Respiratory, CNS, & Endocrine Agents

Key Takeaways Explain This Topic AI

SABAs and LABAs stimulate beta-2 receptors to increase cAMP, whereas SAMAs and LAMAs block M3 receptors to prevent acetylcholine-induced bronchoconstriction.

Tricyclic antidepressants (TCAs) carry a high risk of cardiotoxicity in overdose due to cardiac sodium channel blockade, presenting as QRS widening.

Irreversible MAOIs require a strict low-tyramine diet and a 14-day washout period (5 weeks for fluoxetine) when switching antidepressants to prevent hypertensive crisis or serotonin syndrome.

Sodium valproate is highly teratogenic (neural tube defects) and must be avoided in female patients of childbearing potential unless strict safety measures are met.

SGLT2 inhibitors block renal glucose reabsorption causing glucosuria, and must be withheld during acute illness or prior to surgery to avoid euglycaemic DKA.

Last updated: July 2026

Mechanisms of Action: Respiratory, CNS, & Endocrine Agents

This section details the pharmacology and clinical application of drug classes targeting the respiratory system, central nervous system, and endocrine pathways, in accordance with the Australian Medicines Handbook (AMB) and national guidelines.

Respiratory Agents (Asthma & COPD)

Pharmacological management of obstructive airway diseases involves bronchodilators (relievers and symptom controllers) and anti-inflammatory agents (preventers).

1. Beta-2 Adrenoceptor Agonists

Short-Acting (SABA: Salbutamol, Terbutaline): Provide rapid bronchodilation (onset <5 minutes, duration 4-6 hours) for acute symptom relief.

Long-Acting (LABA: Salmeterol, Formoterol): Used for maintenance therapy. Formoterol has a rapid onset of action, allowing its use as both a reliever and controller in Single Inhaler Maintenance and Reliever Therapy (SMART).

Mechanism of Action: Bind to beta-2 receptors on bronchial smooth muscle, stimulating adenylyl cyclase to increase intracellular cyclic AMP (cAMP). This activates protein kinase A, leading to smooth muscle relaxation and bronchodilation.

Systemic Side Effects: Tremor (activation of beta-2 receptors in skeletal muscle), tachycardia (direct cardiac beta-2 activation and reflex baroreceptor response), and hypokalaemia (stimulation of the Na+/K+ ATPase pump, driving potassium into cells).

2. Anticholinergics (Muscarinic Antagonists)

Short-Acting (SAMA: Ipratropium) & Long-Acting (LAMA: Tiotropium, Glycopyrronium): Primarily used in Chronic Obstructive Pulmonary Disease (COPD), though LAMA is also an option in severe asthma.

Mechanism of Action: Competitively antagonize muscarinic M3 receptors on bronchial smooth muscle, blocking the bronchoconstrictor effects of acetylcholine released from vagal nerve endings.

Adverse Effects: Dry mouth (most common), urinary retention, constipation, and metallic taste.

Safety Warning: Avoid eye contact with inhaler aerosol or powder, as it can cause pupillary dilation and precipitate acute narrow-angle glaucoma.

3. Inhaled Corticosteroids (ICS: Fluticasone, Budesonide, Ciclesonide)

Mechanism of Action: Diffuse into target cells and bind to glucocorticoid receptors. The complex translocates to the nucleus, where it represses pro-inflammatory genes (e.g., cytokines, adhesion molecules) and upregulates anti-inflammatory genes.

Adverse Effects: Local effects include oral candidiasis (thrush) and dysphonia (hoarseness).

Counselling: Patients must rinse their mouth with water and spit it out after each use to clear deposited drug. Using a spacer with pressurized metered-dose inhalers (pMDIs) reduces oropharyngeal deposition and increases lung delivery.

  • Central Nervous System (CNS) Agents
  • Antidepressants

Class Examples Primary Mechanism Key Adverse Effects and Risks

SSRIs Sertraline, Escitalopram, Fluoxetine Inhibit the Serotonin Transporter (SERT), increasing synaptic serotonin. GI upset, sexual dysfunction, hyponatraemia/SIADH (especially in elderly), increased bleeding risk. Escitalopram causes dose-dependent QTc prolongation.

SNRIs Venlafaxine, Duloxetine, Desvenlafaxine Inhibit both SERT and the Norepinephrine Transporter (NET). Similar to SSRIs, plus dose-dependent hypertension (noradrenergic effect, especially venlafaxine >150 mg/day) and excessive sweating.

TCAs Amitriptyline, Nortriptyline, Clomipramine Inhibit SERT and NET; also block H1, M1, alpha-1, and cardiac sodium channels. Sedation (H1 block), orthostatic hypotension (alpha-1 block), anticholinergic effects (M1 block). Highly toxic in overdose.

MAOIs Phenelzine, Tranylcypromine, Moclobemide Inhibit Monoamine Oxidase (MAO-A and/or MAO-B), preventing monoamine breakdown. Postural hypotension, sleep disturbance. High risk of hypertensive crisis (tyramine interaction) and serotonin syndrome.

Critical Overdose and Interaction Risks:

TCA Overdose: TCA overdose is life-threatening. Blockade of cardiac fast sodium channels causes QRS widening, ventricular arrhythmias, and refractory hypotension. Treatment requires intravenous sodium bicarbonate.

MAOI Washout Periods: Irreversible MAOIs (phenelzine, tranylcypromine) inhibit MAO permanently. A 14-day washout period is required when switching to or from other antidepressants to avoid serotonin syndrome or hypertensive crisis. Switching from fluoxetine to an MAOI requires a 5-week washout due to the long half-life of its active metabolite, norfluoxetine.

Tyramine ('Cheese') Reaction: Irreversible MAOIs prevent intestinal breakdown of dietary tyramine (found in aged cheeses, yeast extracts like Vegemite, and red wine). Tyramine enters systemic circulation and displaces norepinephrine from synaptic vesicles, causing a severe hypertensive crisis.

Benzodiazepines (e.g., Diazepam, Temazepam, Lorazepam)

Mechanism: Positive allosteric modulators of the GABA_A receptor. They bind to the interface of alpha and gamma subunits, increasing the frequency of chloride channel opening in response to GABA. This results in chloride influx, membrane hyperpolarization, and neuronal inhibition.

Risks: Sedation, anterograde amnesia, respiratory depression, tolerance, physical dependence, and severe withdrawal symptoms. Flumazenil (a competitive benzodiazepine antagonist) can reverse overdose but can precipitate acute withdrawal seizures in dependent patients.

Anticonvulsants

Phenytoin: Blocks voltage-gated sodium channels. It displays non-linear (zero-order) pharmacokinetics within the therapeutic range, meaning minor dose increases can produce toxic serum concentrations. Adverse effects include gingival hyperplasia, hirsutism, nystagmus, and ataxia. It is a potent CYP enzyme inducer.

Carbamazepine: Blocks sodium channels. It is unique in inducing its own metabolism (auto-induction). It is associated with severe cutaneous reactions (SJS/TEN), strongly linked to the HLA-B*1502 allele in patients of Asian descent.

Sodium Valproate: Increases GABA concentrations, blocks sodium channels, and inhibits T-type calcium channels. It is highly teratogenic, causing neural tube defects and cognitive impairment in offspring. In Australia, it must be avoided in female patients of childbearing potential unless no alternative exists.

Levetiracetam: Binds to synaptic vesicle protein SV2A, modulating neurotransmitter release. It is renally cleared with minimal CYP interactions, but can cause behavioural side effects ('Keppra rage' - irritability, depression, aggression).

  • Endocrine Agents (Antidiabetic Medications)
  • 1. Metformin (Biguanide)

Mechanism of Action: Activates AMP-activated protein kinase (AMPK), leading to:

Decreased hepatic gluconeogenesis (primary effect).

Increased peripheral insulin sensitivity and glucose uptake.

Delayed intestinal glucose absorption.

Clinical Safety: Does not cause hypoglycaemia when used as monotherapy. High incidence of transient GI side effects (diarrhoea, cramping). Associated with a rare risk of lactic acidosis. Metformin must be withheld prior to iodinated contrast media procedures in patients with eGFR <60 mL/min or history of heart failure/hepatic impairment, and restarted 48 hours later if renal function is stable.

2. Sulfonylureas (e.g., Gliclazide, Glimepiride)

Mechanism of Action: Bind to the sulfonylurea receptor 1 (SUR1) on pancreatic beta cells, blocking ATP-sensitive potassium (K_ATP) channels. This depolarizes the cell membrane, opening voltage-gated calcium channels, leading to calcium influx and exocytosis of insulin.

Adverse Effects: Significant risk of hypoglycaemia (especially in elderly and renally impaired patients) and weight gain.

3. SGLT2 Inhibitors (e.g., Dapagliflozin, Empagliflozin)

Mechanism of Action: Inhibit the Sodium-Glucose Co-transporter 2 (SGLT2) in the proximal convoluted tubule of the nephron, blocking the reabsorption of filtered glucose and promoting glucosuria.

Clinical Benefits: Provide significant cardiovascular protection (reduction in heart failure hospitalisations) and slow chronic kidney disease progression.

Adverse Effects: Mycotic genital infections (thrush), urinary tract infections, volume depletion, and euglycemic diabetic ketoacidosis (DKA).

Clinical Counselling: SGLT2 inhibitors must be withheld during acute illness ('sick day rules') or 2 to 3 days before major surgery to minimize DKA risk.